Novo Nordisk A/S





Market Closed - Nasdaq Copenhagen 10:59:52 2024-05-22 am EDT After market 11:20:00 am
923 DKK -0.45% Intraday chart for Novo Nordisk A/S 923 +0.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novo Nordisk Confirms Fire at Office Building in Denmark; No Injuries Reported MT
US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin RE
Novo Nordisk Faces Second Fire at Danish Headquarters Within a Week MT
Fire Breaks Out in Novo Nordisk Denmark Office Building MT
European shares to hit pause before rising again in 2025 RE
Novo Nordisk Hit by Second Fire in a Week DJ
Novo Nordisk site in Denmark hit by fire RE
Indices: On top of the world Our Logo
Eli Lilly Wins Chinese Approval for Diabetes Drug MT
Australia to ban knock-offs of popular weight-loss drugs Ozempic, Mounjaro RE
Health Care Up as Eli Lilly Hits Record High - Health Care Roundup DJ
Two US asset managers launch weight-loss ETFs RE
Most Patients Discontinue Weight-Loss Drugs in US Before Health Benefits Show, Report Says MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell; Hims & Hers Health to Advance, AMC Entertainment to Decline MT
Nestle set to sell $5 pizza, sandwiches for Wegovy, Ozempic users RE
Eli Lilly's diabetes drug tirzepatide gets approval in China RE
AstraZeneca aims for $80 bln in total revenue by 2030 RE
US Equity Markets Close Mixed Monday After Fed Officials' Remarks MT
Novo Nordisk's Wegovy May Be More Effective for Patients With Specific Genes, Study Shows MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Ease Monday Afternoon MT
Sector Update: Health Care MT
Hims & Hers Health Adds Compounded Weight Loss Injections; Shares Rise MT
Arecor Therapeutics' Investigational Insulin Shows Fast Absorption in Early-stage Study MT
Genetic profile may predict best response to weight-loss drug Wegovy RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
927.2 DKK
Average target price
909.2 DKK
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.